Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer RNAi Patents to IDT

NEW YORK, Feb. 28 (GenomeWeb News) - Integrated DNA Technologies has taken a non-exclusive license from Alnylam to provide RNAi research products and services under the Kreutzer-Limmer patent family, Alnylam said today.

 

The Kreutzer-Limmer patent family, owned exclusively by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells.

 

Alnylam said that the IDT deal brings to 20 the number of license agreements it has executed, including 11 with research product suppliers.

 

Financial terms of the deal were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.